Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2015 - 2022)

Gyre Therapeutics (GYRE) reported Asset Writedowns and Impairment of $200000.0 for Q1 2022, up 49.25% quarter-over-quarter from $134000.0 in Q2 2015.

Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2015 - 2022) Analysis & Trends

Gyre Therapeutics (GYRE) has 2 years of Asset Writedowns and Impairment data on file, last reported at $200000.0 in Q1 2022.

Asset Writedowns and Impairment for Q1 2022 came in at $200000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $200000.0 (changed N/A YoY), and the FY2022 annual result was $200000.0, changed N/A from the prior year.
Asset Writedowns and Impairment advanced to $200000.0 in Q1 2022 per GYRE's latest filing, from $134000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $200000.0 in Q1 2022 and troughed at $200000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Gyre Therapeutics	554.75 Mn	540.62 Mn	8.38 Mn

Download Data